I’ve run BPC-157 twice for my shoulder (250mcg 2x/day subcu, 4-week cycles) and I’m currently running TB-500 pre-run for my knee. The biggest difference in how I think about them is where I pin and why. BPC hyperlocal is the play for targeted tissue work. My shoulder protocol was 250mcg 2x/day subcu near the site.
If the issue is local tissue quality, that’s where you want it. If it’s just general wear from training volume, bpc won’t fix your programming. TB-500 reads more systemic. So for the knee, while I’m still injecting subcu, I’m not doing it right at the knee joint with the same laser focus.
The distribution is different, so the site choice matters less for direct local action and more for overall systemic availability. It’s about optimizing for two different distributions. Rotating sites on both without that distinction feels like you’re missing the point of how they actually work. I track injection site, pain (1-10), and ROM daily in CareClinic.
The correlation view helps me see if a specific site change lines up with an outcome shift, or if it’s just noise.
That “BPC hyperlocal is the play” is accurate. What it means is subq bpc stays put.
it’s hypovascular tissue and won’t distribute far from the pin, so absent systemic effects in logs can be distribution, not a wrong mechanism. Your distinction between bpc and tb-500 is good, but the *
ymmv. if the issue is local tissue quality, what’s the actual mechanism that makes one distribution “systemic” versus “hyperlocal” to the point where rotating sites changes the how it works part?
ymmv. when you’re looking for whether “a specific site change lines up with an outcome shift, or if it’s just noise,” how are you actually isolating for other systemic stuff? i’ve seen my own pain levels
that distinction around local vs. systemic delivery is pretty fundamental.
with bpc-157 there’s preclinical evidence for a more contained local effect, which aligns with your “hyperlocal” framing bc its mechanism often involves direct trophic factors and local nitric oxide synthase modulation. but tb-500’s physiological ubiquity and its role in actin dynamics
the local vs systemic approach for site choice makes total sense, most people run them that way. but i’d push on the “pain (1-10)” correlation view for an outcome shift with specific site changes, tbh. that metric is gonna fold in so many other things like sleep, how knackered you are, stress, all at once, so isolating a tissue-level repair signal from that is proper hard.
Agreed on “optimizing for two different distributions,” that’s the core. With a knee though, you’re dealing with a synovial joint that’s well-innervated, not like a labrum or tendon.
That distinction changes what mechanisms are even on the table for any compound you’re running there. And for BPC
so that distinction about where to pin really hits, especially “if the issue is local tissue quality, that’s where you want it.” i’m still trying to figure out my shoulder labrum and whether it’s the actual tissue or if there’s nerve stuff from the injury itself making it act up. that’s where the bpc local 🔥
The “optimizing for two different distributions” part is a good read on how these compounds differ. But for a knee, the question of peri-articular BPC versus systemic TB-500 needs to start with mechanism, not just distribution. They’re mechanistically different tools, and peri-articular BPC in a loaded joint is doing